Drugs that contain Fluticasone Furoate; Vilanterol Trifenatate
1. Drug name - BREO ELLIPTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(5 months from now) | |
| US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(2 years from now) | |
| CN1585633A | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN103288793A | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN103288793B | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN101701006B | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN101701006A | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN1585633B | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| IN212714B | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases. |
Sep, 2022
(24 days ago) | |
| IN200400346P2 | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases. |
Sep, 2022
(24 days ago) | |
| EP2042168B1 | GLAXO GRP LTD | Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| EP2042168A1 | GLAXO GRP LTD | Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| EP1425001B1 | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2027
(4 years from now) | |
| EP1425001A1 | GLAXO GRP LTD | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(5 years from now) | |
| US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(5 years from now) | |
| US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(6 years from now) | |
| US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(7 years from now) | |
| US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(8 years from now) | |
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.1MG/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.2MG/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.